Skin itching in perimenopause is one of the more disorienting symptoms because it often occurs without a visible rash or obvious cause. Women describe itching that moves around the body, crawling or tingling sensations under the skin (sometimes called formication), patches of hypersensitivity where touch feels irritating, and a general increase in skin reactivity to fabrics, cosmetics, and temperature.

These symptoms have identifiable causes rooted in the same hormonal changes that drive other perimenopausal symptoms. They are underreported partly because women assume they are unrelated to menopause and partly because the connection is not widely recognised in clinical practice.

How Estrogen Maintains Skin

Skin is an estrogen-responsive tissue. Estrogen receptors are present in keratinocytes (the primary cells of the outer skin layer), fibroblasts (which produce collagen and elastin), and the sebaceous glands.[1]

Collagen production. Estrogen stimulates collagen synthesis. In the first five years after menopause, skin collagen content declines by approximately 30%, with further losses of about 2% per year thereafter.[2] Thinner skin has a less effective barrier, becomes more permeable to irritants, and dries out more readily.

Sebum production. Sebaceous glands produce sebum, the oily substance that forms part of the skin's protective barrier. As estrogen declines, sebum production falls in some women, contributing to dryness and reduced barrier function.[3]

Histamine regulation. Estrogen modulates mast cell activity and histamine release. Mast cells are immune cells present in skin that release histamine in response to allergens, physical stimuli, and stress. Estrogen decline may alter mast cell sensitivity in ways that increase histamine reactivity, contributing to itching that does not follow the pattern of a typical allergic response.

Nerve sensitivity. Estrogen influences the threshold at which nerve fibres in the skin fire. Lower estrogen is associated with changes in cutaneous nerve function, including increased sensitivity of C-fibres, the fibres responsible for conveying itch signals.[4] This peripheral sensitisation is one mechanism behind formication and the increased sensitivity to touch and fabric that many perimenopausal women report.

Formication: The Crawling-Skin Sensation

Formication, from the Latin for ant (formica), describes the sensation of insects crawling on or under the skin. It is generated by real changes in cutaneous nerve firing rather than by psychological disturbance.

Formication in perimenopause is not rare. A survey of menopausal symptoms by the Women's Health Concern found that approximately 20% of women reported tingling or crawling skin sensations during the menopausal transition. Despite this prevalence, it often goes unmentioned in GP consultations because women are uncertain whether it belongs in the category of menopausal symptoms.

The mechanism is primarily neurological: declining estrogen alters the sensory threshold of cutaneous nerves, leading to spontaneous or exaggerated firing perceived as movement, tingling, or crawling. It is more common in women with existing anxiety, because anxiety increases sympathetic nervous system tone and sensitises sensory pathways, but it occurs independently of anxiety as well.

Vulvar and Genital Itching

Vulvar and genital itching has a different primary mechanism from generalised skin itch. The dominant cause is genitourinary syndrome of menopause (GSM): the thinning and inflammation of the vulvar, vaginal, and urethral tissues that occurs with estrogen loss.

Genital itching caused by GSM is persistent, often worsening with friction from clothing or sexual activity, and is associated with dryness, discomfort, and sometimes pain. It responds specifically to local vaginal estrogen, which restores tissue health at the source. Generalised emollients and antihistamines are much less effective here because the underlying cause is tissue atrophy rather than skin barrier failure or mast cell activation.

Vulvar lichen sclerosus is a separate condition that produces itching, thinning, and whitening of the vulvar skin. It is more common in postmenopausal women and requires specific treatment (potent topical corticosteroids). Any persistent vulvar itching with visible skin changes warrants clinical assessment to distinguish GSM from lichen sclerosus or other conditions.

What Helps

Emollients and barrier repair

For generalised dry, itchy skin, the primary intervention is restoring the skin barrier with regular emollient application. Emollients work by reducing transepidermal water loss, the main driver of dry skin and itch. Applying emollient immediately after bathing while the skin is still slightly damp maximises absorption.

Fragrance-free formulations reduce the risk of contact sensitisation in skin that has become more reactive. Ingredients with proven barrier-repair properties include ceramides, niacinamide, and glycerol. Petroleum jelly (white soft paraffin) remains one of the most effective and inexpensive options.

Avoiding triggers

Perimenopausal skin is more reactive to physical and chemical irritants. Common aggravating factors include:

  • Synthetic fabrics in direct contact with skin (particularly against the chest, back, and thighs)
  • Long, hot showers or baths, which strip sebum
  • Fragranced soaps and shower gels
  • Laundry detergents with high fragrance content
  • Alcohol-containing skincare products
  • Sudden temperature changes

Antihistamines

Sedating antihistamines such as chlorphenamine can reduce itching from a histamine-mediated component, and the sedating effect is useful at night when itch tends to be most bothersome. Non-sedating antihistamines (cetirizine, loratadine) are better tolerated for daytime use but less effective at night. The evidence for antihistamines in menopausal pruritus specifically is limited; they are an empirical trial rather than a targeted treatment.

HRT

For women whose generalised skin itch is primarily driven by estrogen loss, systemic HRT addresses the underlying cause. Clinical studies have found that HRT improves skin moisture content, collagen thickness, and barrier function in postmenopausal women.[5] The benefit to itch follows from these tissue changes. Transdermal HRT (patch, gel, spray) provides direct local skin exposure in addition to systemic absorption, which may be an additional advantage for skin symptoms.

Topical local estrogen for genital itch

Local vaginal estrogen (cream, pessary, or ring) is the specific and highly effective treatment for vulvar and vaginal itching caused by GSM. It is safe for long-term use, does not require a progestogen to protect the endometrium at standard doses, and produces measurable improvement in tissue quality within 8–12 weeks.[6]

When to seek assessment

Persistent generalised itch that does not respond to emollients and has no obvious skin-surface cause warrants blood tests to exclude systemic causes. Conditions that produce systemic pruritus include thyroid dysfunction, iron deficiency, liver conditions, and renal disease, all more prevalent in midlife women. Any localised skin change accompanying the itch (thickening, whitening, colour change, ulceration) warrants clinical review.

## References [1] Verdier-Sevrain, S., Bonte, F., Gilchrest, B. (2006). Biology of estrogens in skin: Implications for skin aging. Experimental Dermatology, 15(2), 83–94. https://doi.org/10.1111/j.0906-6705.2005.00377.x

[2] Brincat, M., Moniz, C. F., Studd, J. W., et al. (1983). Sex hormones and skin collagen content in postmenopausal women. BMJ, 287(6402), 1337–1338. https://doi.org/10.1136/bmj.287.6402.1337

[3] Pochi, P. E., Strauss, J. S., Downing, D. T. (1979). Age-related changes in sebaceous gland activity. Journal of Investigative Dermatology, 73(1), 108–111. https://doi.org/10.1111/1523-1747.ep12532792

[4] Rukwied, R., Dusch, M., Kreiter, A., Schertel, A., Schmelz, M. (2008). Nociceptor sensitization to electrical stimulation is increased in healthy volunteers after topical application of capsaicin: A proof-of-concept study. Experimental Dermatology, 17(9), 789–793.

[5] Sator, P. G., Schmidt, J. B., Rabe, T., Zouboulis, C. C. (2004). Skin aging and sex hormones in women: Clinical perspectives for intervention by hormone replacement therapy. Experimental Dermatology, 13(Suppl 4), 36–40. https://doi.org/10.1111/j.1600-0625.2004.00259.x

[6] Suckling, J., Lethaby, A., Kennedy, R. (2006). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews, 4, CD001500. https://doi.org/10.1002/14651858.CD001500.pub2